₹0.17
(Market cap
₹57 Cr
Recently Viewed
Clear AllMarket cap
₹57 Cr
Revenue (TTM)
₹84 Cr
P/E Ratio
--
P/B Ratio
-0.6
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹-35 Cr
ROE
0 %
ROCE
-9.1 %
Industry P/E
48.2
EV/EBITDA
-44.8
Debt to Equity
-5.1
Book Value
₹-12.4
EPS
₹-4.2
Face value
2
Shares outstanding
82,913,915
CFO
₹1,339.60 Cr
EBITDA
₹794.79 Cr
Net Profit
₹-223.49 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Vivimed Labs
| -61.1 | 17.8 | -6.0 | -- | 1.9 | -28.8 | -22.5 |
|
BSE Healthcare
| 2.9 | 4.5 | 8.1 | 6.7 | 25.3 | 14.0 | 11.1 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
Vivimed Labs
| -49.5 | 18.6 | 43.3 | -66.3 | -65.3 | 16.1 | 1.0 |
|
BSE Small Cap
| -1.8 | 62.8 | 32.1 | -6.8 | -23.4 | 59.6 | 1.8 |
|
BSE Healthcare
| -12.1 | 20.9 | 61.4 | -3.5 | -5.9 | 0.5 | -12.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Vivimed Labs
|
6.9 | 57.0 | 83.6 | -35.0 | -41.5 | -- | -- | -0.6 |
| 2,494.6 | 20,418.7 | 1,215.1 | 284.8 | 28.7 | 21.1 | 71.2 | 13.4 | |
| 764.6 | 15,018.4 | 7,266.8 | 627.5 | 11.9 | 12.6 | 23.9 | 2.8 | |
| 694.9 | 17,224.4 | 5,092.5 | 545.5 | 15.9 | 14.1 | 31.6 | 3.9 | |
| 955.0 | 15,208.2 | 7,918.4 | 429.9 | 10.7 | 7.2 | 35.1 | 2.3 | |
| 1,089.9 | 19,524.8 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 12.5 | 2.2 | |
| 1,831.4 | 20,959.0 | 1,419.3 | 20.1 | 8.4 | 0.5 | 1042.6 | 3.6 | |
| 168.8 | 22,431.1 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.8 | |
| 438.0 | 17,644.7 | 3,720.2 | 352.1 | 13.7 | 8.2 | 50.1 | 3.7 | |
| 1,437.5 | 23,412.7 | 3,151.0 | -10.0 | 8.4 | 2.5 | 1064.2 | 5.1 |
2 min read•By Research Desk
Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India. It operates in two segments,... Speciality Chemicals Business and Pharma Business. The company provides APIs and intermediates to generic and ethical companies; and branded formulations in therapeutic segments, such as ophthalmic, nutraceuticals, dermatology, and pain, as well as contract manufacturing of capsules and tablets, syrups and liquids, and nasal sprays and ointments. It also offers active ingredients primarily for hair dye and photochromic applications. Additionally, the company manufactures Favulous tablets for the treatment of mild to moderate cases of Covid-19. Its products are used in home, personal, and industrial care segments. The company also exports its products. The company was incorporated in 1988 and is based in Hyderabad, India. Read more
Incorporated
1988
Chairman
Manohar Rao Varalwar
Managing Director
Santosh Varalwar
Headquarters
Bidar, Karnataka
Website
Looking for more details about Vivimed Labs Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View Announcements
The share price of Vivimed Labs Ltd is ₹6.88 (NSE) and ₹6.87 (BSE) as of 27-Apr-2026 IST. Vivimed Labs Ltd has given a return of 1.91% in the last 3 years.
Since, TTM earnings of Vivimed Labs Ltd is negative, P/E ratio is not available.
The P/B ratio of Vivimed Labs Ltd is -0.56 times as on 27-Apr-2026, a 116 discount to its peers’ median range of 3.57 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
0.00
|
0.00
|
|
2024
|
0.00
|
0.00
|
|
2023
|
0.00
|
38.89
|
|
2022
|
0.00
|
0.37
|
|
2021
|
0.00
|
0.33
|
The 52-week high and low of Vivimed Labs Ltd are Rs 29.40 and Rs 5.15 as of 27-Apr-2026.
Vivimed Labs Ltd has a market capitalisation of ₹ 57 Cr as on 27-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Vivimed Labs Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.